Answers are grounded in this paper and cite their sources.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that disproportionately affects women. A significant number of individuals with AD experience sleep disruptions, as do many women navigating menopause, a transition marked by a decline in sex hormones. These shared sleep disturbances are primarily linked to the disruption of circadian rhythms. Although individual research on circadian dysfunction in AD and menopause is extensive, a critical gap remains in understanding the integrated role of circadian biomarkers across both conditions. To address this gap, we conducted a comprehensive review of relevant articles from MEDLINE (via PubMed), Scopus, and Web of Science. Our primary research question was to investigate how menopause may contribute to AD pathogenesis through circadian dysfunction and related sleep disturbances. A review of articles revealed that four circadian biomarkers are altered in both conditions: reduced melatonin secretion, elevated orexin levels, hypertension, and changes in core clock genes. We proposed that alterations in these biomarkers during menopause, driven by age-related changes and the decline of estrogen and progesterone, may potentially increase the risk of developing AD or accelerate the progression of pre-existing AD and related sleep disturbances. Based on this hypothesis, we also identified potential shared therapeutic approaches that may target these pathways. These include menopausal hormone therapy and chronotherapeutic interventions such as melatonin supplementation, orexin receptor antagonists, and light therapy. This review underscores the need for further research into the integrated role of circadian disruption in the link between menopause and AD.
No takes yet. Share an insight, caveat, or question.
Nejadrostam et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: